Sign in
Stories
AlloVir Faces Class Action Lawsuit
Share
AlloVir Faces Class Action Allegations
Assertio Holdings Faces Securities Law I...
Biotech Legal Updates: Lawsuits and Dism...
AlloVir Class Action Lawsuit Filed
AlloVir Faces Lawsuit Over Statements
AlloVir Faces Securities Fraud Lawsuit
Overview
API
The Gross Law Firm alerts AlloVir, Inc. shareholders of a class action lawsuit, claiming the company issued deceptive statements about the posoleucel Phase 3 Studies. Shareholders have until March 19, 2024, to participate.
Ask a question
Could this case lead to regulatory changes in how biotech firms report study results?
How might this lawsuit impact AlloVir's reputation and stock performance?
What measures can companies take to ensure transparent communication with shareholders?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage